Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency by unknown
RESEARCH ARTICLE Open Access
Disease severity in K/BxN serum transfer-induced
arthritis is not affected by IL-33 deficiency
Praxedis Martin1,2, Dominique Talabot-Ayer1,2, Christian Alexander Seemayer3, Solenne Vigne1,2,
Céline Lamacchia1,2, Emiliana Rodriguez1,2, Axel Finckh1, Dirk E Smith4, Cem Gabay1,2 and Gaby Palmer1,2*
Abstract
Introduction: Interleukin (IL)-33 is a cytokine of the IL-1 family, which signals through the ST2 receptor. Previous
work suggested implication of the IL-33/ST2 axis in the pathogenesis of human and mouse arthritis. Here, we
directly investigated the role of endogenous IL-33 in K/BxN serum transfer-induced arthritis by using IL-33
knockout (KO) mice.
Methods: Arthritis was induced by injection of complete K/BxN serum or purified IgG. Disease severity was
monitored by clinical and histological scoring.
Results: K/BxN serum transfer induced pronounced arthritis with similar incidence and severity in IL-33 KO and
wild-type (WT) mice. In contrast, disease development was significantly reduced in ST2 KO mice. IL-33 expression in
synovial tissue was comparable in arthritic WT and ST2 KO mice, and absent in IL-33 KO mice. Transfer of purified
arthritogenic IgG instead of complete K/BxN serum also resulted in similar arthritis severity in IL-33 KO and WT
mice, excluding a contribution of IL-33 contained in the serum of donor mice to explain this result. We
investigated additional potential confounding factors, including purity of genetic background, but the mechanisms
underlying reduced arthritis in ST2 KO mice remained unclear.
Conclusions: The data obtained with IL-33 KO mice indicate that endogenous IL-33 is not required for the
development of joint inflammation in K/BxN serum transfer-induced arthritis. On the contrary, arthritis severity was
reduced in ST2 KO mice. This observation might relate to IL-33 independent effects of ST2, and/or reveal the
existence of confounding variables affecting the severity of joint inflammation in these KO strains.
Introduction
Interleukin (IL)-33 is the most recently discovered mem-
ber of the IL-1 cytokine family (see [1] for review). IL-33,
like IL-1a, is a dual-function protein, displaying both
nuclear and extracellular effects. The latter are mediated
by its binding to an IL-1 receptor family member called
ST2 (IL1RL1). ST2 exists in two isoforms generated by
alternative splicing [2]. The short isoform (sST2) acts as a
soluble decoy receptor [3]. The long signaling ST2 recep-
tor isoform (ST2l) is expressed in many hematopoietic
cells, including a number of innate immune cells, which
are involved in T helper 2 (Th2)-type response. Consis-
tently, injection of recombinant IL-33 induces or amplifies
type 2 immune effects in different mouse models [4-6]. In
addition IL-33 acts on neutrophils, Th1 cells, natural killer
cells, and mast cells, as well as on endothelial cells, to
induce proinflammatory effects, so that a role for IL-33 in
host defense and immunopathology independently of Th2
immunity has also been suggested [7-9]. IL-33 is constitu-
tively expressed in stromal cells, including epithelial cells
and specialized fibroblasts, as well as in endothelial cells in
human, but only to a limited extent in mouse [10,11]. It
has been proposed that, upon tissue damage, constitutively
expressed IL-33 leaks from necrotic cells and acts as an
alarmin to initiate or amplify immune responses [10,12].
Previous work suggested a functional role of the IL-33/
ST2 axis in the pathogenesis of human and mouse arthritis.
In human rheumatoid arthritis (RA), IL-33 levels in serum
and synovial fluid are elevated [13-15] and strong IL-33
expression can be detected in endothelial cells and fibro-
blasts in human RA synovium [16,17]. In mouse models of
experimental arthritis involving active immunization, such
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as collagen- and antigen-induced arthritis, the use of ST2
knockout (KO) mice, ST2 blockade or injection of sST2
led to decreased immune responses and severity of arthri-
tis, while injection of recombinant IL-33 increased arthritis
severity, suggesting a pathogenic role for IL-33, signaling
through ST2, in these experimental models [18-21]. Two
studies investigated involvement of IL-33 in the inflamma-
tory effector phase of arthritis, as it can be studied in the
K/BxN serum transfer-induced model [22,23]. The first
study concluded to a pathogenic role of IL-33 based on
reduced arthritis severity in ST2 KO mice and increased
disease severity after injection of IL-33 [22]. The second
study reported an opposite effect of IL-33 injection, which
suppressed joint inflammation by enhancing the produc-
tion of Th2 cytokines and upregulating the inhibitory
Fc receptor FcgRIIB on macrophages [23].
In the present study, we directly investigated the role of
endogenous IL-33 in K/BxN serum transfer-induced
arthritis using IL-33 KO mice and compared the results to
those obtained using ST2 KO mice. We confirm decreased
severity of arthritis in ST2 KO, but not in IL-33 KO mice,
suggesting that endogenous IL-33, although expressed in
the synovium, is not required for the development of
arthritis in this model.
Materials and methods
Mice
C57BL/6 mice were obtained from Janvier (Le Genest-St-
Isle, France). IL-33 KO mice (B6.129Sv-Il33) were gener-
ated at Amgen Inc. (Thousand Oaks, CA, USA) by
targeting of the Il33 gene in 129Sv ES cells resulting in
the deletion of six out of the seven coding exons [24].
Genotyping was performed by a 3-primer PCR combin-
ing a common forward primer (5’-TGC TGA ATT TTA
TTC TCC CCC C-3’) with reverse primers specific for
the wild-type (WT) (5’-GCC CGT CTT CAT GTT GAA
ATA-3’) or the KO (5’-GCT CAT TCC TCC CAC TCA
TGA-3’) allele. IL-33 KO mice were backcrossed to the
C57BL/6 background for six generations by speed con-
genics and considered to be 100% congenic based on
analysis of a 377 SNIP panel (Taconic, Hudson, NY,
USA). ST2 KO C57BL/6 mice (Il1rl1tm1Anjm, [25]) were
obtained from the MRC Laboratory of Molecular Biology
(Cambridge, UK). For arthritis experiments, local colo-
nies of WT, IL-33 KO and ST2 KO mice were established
at the Centre Médical Universitaire in Geneva. KRN T
cell receptor transgenic mice [26] were provided by the
Institut de Génétique et de Biologie Moléculaire et Cellu-
laire (Strasbourg, France) and maintained on a C57BL/6
background (K/B). NOD/Lt mice were purchased from
Charles River (L’Arbresle, France). Mice were housed
under conventional or low barrier conditions. Institu-
tional approval was obtained for all animal experiments
(Geneva Veterinarian Office, licenses 31.1.1005/3402/2,
3402/2-C and 3402/2-R).
Biological reagents
Blocking anti-ST2, anti-IL-1RI and isotype-matched con-
trol antibodies were generated at Amgen Inc. Cell culture
media were obtained from Invitrogen Life Technologies
(Basel, Switzerland). Recombinant mouse IL-33 was pur-
chased from Enzo Life Sciences (Lausen, Switzerland),
human IL-1b and mouse IL-18 from R&D Systems
(Abingdon, UK), and purified lipopolysaccharide (LPS)
from Fluka (Escherichia coli 055:B5, Buchs, Switzerland).
Murine IL-36b was produced at Amgen Inc. as an
N-terminal truncation variant [27].
K/BxN serum transfer-induced arthritis
Arthritic K/BxN mice were generated by crossing K/B
mice with NOD/Lt mice, adult arthritic K/BxN mice
were bled, and the sera were pooled. Age-matched female
recipient WT, IL-33 KO or ST2 KO C57BL/6 mice were
injected with pooled serum (200 μl, i.p.) on days 0 and 2.
Alternatively, WT C57BL/6 mice were injected with
pooled serum (200 μl, i.p.) on days 0 and 2, as well as
with a monoclonal murinized immunoglobulin G (IgG1)-
blocking anti-ST2 antibody (150 μg/mouse), a monoclo-
nal murinized IgG1-blocking anti-IL-1R1 antibody
(150 μg/mouse), or a monoclonal mouse IgG1 antibody
directed against an irrelevant human antigen that was
used as an isoytpe-matched control antibody (150 μg/
mouse), on day 0 (4 h before injection of K/BxN serum)
and on day 3 (experiment 1), or on days 0 and 2 (4 h
before each injection of K/BxN serum; experiment 2).
Efficacy of the blocking anti-ST2 antibody was demon-
strated previously [24,28]. The development of arthritis
was assessed daily and the severity of arthritis was scored
in a blinded fashion for each paw on a 3-point scale, in
which 0 = normal appearance, 1 = localized edema/
erythema over one surface of the paw, 2 = edema/
erythema involving more than one surface of the paw,
3 = marked edema/erythema involving the whole paw.
The scores of all four paws were added for a composite
score. Mice were sacrificed on day 6.
Purification of the total IgG fraction from K/BxN serum
and induction of arthritis
Serum of arthritic K/BxN mice (20 ml) was purified on
protein A/G Sepharose 4 Fast Flow (GE Healthcare Life
Sciences, Glattbrugg, Switzerland) and dialyzed into PBS
[29]. Recipient WT, IL-33 KO or ST2 KO mice were
injected with the purified IgG fraction (450 μl i.p., corre-
sponding to 200 μl of the initial volume of K/BxN serum)
on days 0 and 2. Mice were assessed for arthritis severity
daily and sacrificed on day 6.
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Histological grading of arthritis
At sacrifice, the right ankle joints were fixed in 10% buf-
fered formalin, decalcified in 15% EDTA, and embedded
in paraffin. Sections were stained with hematoxilin and
eosin or toluidine blue and graded by one pathologist
(CAS) in a blinded manner. The severity of the synovial
inflammation including synovial hyperlasia and the % of
polymorphonulcear (PMN) cell infiltration, as well as the
degree of cartilage erosion and bone destruction were
evaluated utilizing a scoring system ranging from 0 to 4
(0 = normal, 1 = minimal, 2 = moderate, 3 = severe, 4 =
very severe) [30].
RT-qPCR
Left ankles were harvested at sacrifice and RNA was
extracted with Trizol (Invitrogen Life Technologies).
Total RNA (1 μg) was treated with RQ1 DNAse
(Promega, Madison, WI, USA) and reverse transcribed
using SuperScript II Reverse transcriptase (Invitrogen
Life Technologies). Cytokine mRNA levels were assessed
by RT-qPCR using appropriate primers (Table 1) and iQ
SYBR Green Supermix in the iCycler iQ™ Real-Time
PCR Detection System (Bio-Rad Laboratories Inc., Her-
cules, CA, USA). The annealing temperature was 60°C.
Non-reverse-transcribed RNA samples and water were
included as negative controls. RNA expression levels
were calculated using the comparative method (2-ΔCt) for
relative quantification by normalization to Gapdh gene
expression.
Determination of cytokine levels in serum and tissue
lysates
Serum and right wrist joints were harvested at sacrifice.
Joints were homogenized in 500 μl of lysis buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, complete EDTA-free
protease inhibitor cocktail (Roche Diagnostics AG, Rotk-
reuz, Switzerland)). Lysates were cleared by centrifuga-
tion and total protein content was determined with the
DC protein assay kit (Bio-Rad Laboratories Inc.). IL-33
was quantified using a mouse IL-33 Milliplex cytokine
magnetic beads assay (Millipore AG, Zug, Switzerland;
detection limit 1.61 and 4.3 pg/ml in two different kits
used). IL-6 levels were quantified using a DuoSet ELISA
Development System (R&D Systems; detection limit 16
pg/ml).
Immunohistochemistry
IL-33 protein expression was examined in knee joints of
WT and ST2 KO mice using a polyclonal goat anti-IL-
33 antibody (AF3626, R&D Systems). Formalin-fixed,
decalcified, paraffin-embedded sections were deparaffi-
nized and antigen retrieval was performed in a pressure
chamber (Pascal; Dako, Baar, Switzerland) in 0.1 M
Tris-HCl, pH 9.0, 0.01 M EDTA, at 125°C for 30 sec.
Slides were blocked for endogenous peroxidase activity
and incubated with anti-IL-33 antibody (1 μg/ml) in
antibody diluent (number S2022, Dako) overnight at 4°
C. Subsequently, slides were incubated with an anti-goat
HRP antibody (1:500; number SC2304, Santa Cruz Bio-
technology, Inc., Heidelberg, Germany) in antibody dilu-
ent and developed with diaminobenzidine (Dako). To
assess staining specificity, negative controls were per-
formed using knee sections of IL-33 KO mice.
Cell culture
Bone marrow-derived dendritic cells (BMDC) were gen-
erated from WT, IL-33 KO and ST2 KO C57BL/6 mice
as previously described [31]. On day 7, cells were seeded
into triplicate wells of 96-well plates at 105 cells/ml and
cultured without or with 100 ng/ml recombinant IL-33,
IL-1b, IL-36b or IL-18 or LPS for 72 h. IL-6 production
in culture supernatants was assessed by ELISA. Cells
from triplicate wells were pooled and used for total
RNA extraction using the RNeasy kit (Qiagen, Valencia,
CA, USA). Expression of IL-1R family receptors was
quantified by RT-qPCR using appropriate sets of pri-
mers (Table 1).
Microsatellite marker genotyping
IL-33 KO, ST2 KO and WT mice (n = 3 per genotype)
were randomly selected at the end of the experiment
shown in Figure 1 and genotyped for 55 microsatellite
markers as described [32]. In addition, all ST2 KO mice
used in the arthritis experiments described herein were
screened for D1Mit3, D1Mit211, D1Mit75a, D1Mit303,
D6Mit166, D6Mit159, D6Mit102, and D15Mit193 geno-
types using appropriate primers ([32]; see [33] for addi-
tional primer information).
Table 1 Primer sequences for RT-qPCR analysis.
Target GenBank Primer Primer sequence
Il33 NM_133775.2 Il33 fwd 5’-ggtgtggatgggaagaagctg-3’
Il33 rev 5’-gaggactttttgtgaaggacg-3’
Il6 NM_031168.1 Il6 fwd 5’-tgaacaacgatgatgcacttgcaga-3’
Il6 rev 5’-tctgtatctctctgaaggactctggct-3’
Il1r1 NM_008362.2 Il1r1 fwd 5’-gagttacccgaggtccagtgg-3’
Il1r1 rev 5’-gagggctcaggataacagg-3’
Il1rl2 NM_133193.3 Il1rl2 fwd 5’-aaacacctagcaaaagcccag-3’
Il1rl2 rev 5’-agactgcccgattttcctatg-3’
Il18r1 NM_008365.2 Il18r1 fwd 5’-ggagatgagggctactactcctgcg-3’
Il18r1 rev 5’-gtcttcttgcacattagggtctgagctg-3’
Il18rap NM_010553 Il18rap fwd 5’-cccggaagtgctagaagaca-3’
Il18rap rev 5’-acccgcagagcctttttgac-3’
Gapdh NM_008084.2 Gapdh fwd 5’-acggccgcatcttcttgtgca-3’
Gapdh rev 5’-aatggcagccctggtgacca-3’
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Figure 1 Severity of serum transfer-induced arthritis is reduced in ST2, but not in IL-33 KO mice. (A) Incidence of arthritis is shown for
WT (n = 14, dashed line), IL-33 KO (n = 12, gray line), and ST2 KO (n = 10, black line) mice. Incidence was significantly retarded in ST2 KO, as
compared to WT or IL-33 KO mice (P < 0.01, longitudinal model for binomial data). (B-C) Arthritis severity scores (B) and number of affected
paws (C) are shown as the mean ± SEM for WT (dashed line), IL-33 KO (gray line), and ST2 KO (black line) mice. The evolution of severity scores
(B; P = 0.001, mixed model for repeated measures) and final disease severity were significantly decreased in ST2 KO, as compared to WT (*P <
0.05) and IL-33 KO (&P < 0.05) mice. Evolution of the number of affected paws tended to be lower in ST2 KO, as compared to IL-33 KO and WT
mice (P = 0.05, longitudinal model for ordinal data). (D) Clinical scores for inflammation of the right hind paw, which was processed for
histological evaluation, and histological scores for inflammation, polymorphonulcear cell (PMN) infiltration, cartilage and bone erosion are shown
as the mean ± SEM for WT (open columns), IL-33 KO (gray columns), and ST2 KO (black columns) mice. Cartilage and bone erosion were
significantly reduced in ST2 KO, as compared to IL-33 KO mice; &P < 0.05. KO, knockout; WT, wild-type.
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Statistical analysis
To assess differences in the longitudinal evolution of
arthritis outcomes, we used generalized linear mixed mod-
els for repeated measures [34]. Tests were conducted at
error alpha level of 0.05, two-sided and performed with
STATA v. 11 for Windows (StataCorp LP, College Station,
TX, USA). Differences in arthritis severity at the end of the
follow-up were evaluated using the Kruskal-Wallis test.
Significance of differences in histological scores, cytokine
measurements, and mRNA expression was assessed by
ANOVA or Kruskal-Wallis test, as appropriate.
Results
IL-33 and ST2 KO mice display different phenotypes in K/
BxN serum transfer-induced arthritis
We examined incidence and severity of K/BxN serum
transfer-induced arthritis in IL-33 KO, ST2 KO and WT
C57BL/6 mice. Clinical scoring showed reduced inci-
dence and severity of arthritis in ST2 KO mice as com-
pared to WT controls (Figure 1A-C). In contrast,
arthritis development and severity in IL-33 KO mice was
similar to the disease observed in WT mice. Histological
scoring of arthritic ankles on day 6 confirmed a trend
toward reduced inflammation and PMN cell infiltration,
as well as reduced cartilage and bone erosion in ST2 KO
paws (Figure 1D).
On day 6 after induction of arthritis, serum IL-33 levels
were similar in WT and ST2 KO mice (WT, mean: 310 ±
192 pg/ml, range < 1.61 to 1258 pg/ml; ST2KO, 447 ± 287
pg/ml, range < 1.61 to 2142 pg/ml) and comparable to
IL-33 levels measured in naïve WT C57BL/6 mice (n = 17;
294 ± 191 pg/ml, range < 1.61 to 3062 pg/ml) housed in
our conventional mouse facility. IL-33 was undetectable in
the serum of IL-33 KO mice. IL-33 mRNA (Figure 2A)
and protein (Figure 2B) expression in synovial tissues was
similar in arthritic WT and ST2 KO mice, and absent in
IL-33 KO mice. Expression of IL-6 mRNA (Figure 2A)
and protein (Figure 2B) in arthritic paws, monitored as a
marker of inflammation, paralleled severity scores and
tended to be lower in ST2 KO as compared to WT mice.
Strong nuclear IL-33 immunostaining was observed in the
synovial tissue of WT and ST2 KO mice, in cells morpho-
logically consistent with fibroblasts, as well as in other cell
types, which we have not formally identified (Figure 2C).
Interestingly, and in contrast to human RA synovium
[16,17] synovial endothelial cells did not express IL-33. A
similar pattern of IL-33 protein expression was observed
in the synovium of WT and ST2 KO mice, while no IL-33
staining was detected in IL-33 KO mice.
IL-33 and ST2 KO mice display different phenotypes in
arthritis induced by injection of arthritogenic IgG
We wondered whether differences observed between IL-
33 and ST2 KO mice regarding the severity of arthritis
might be related to the existence of confounding vari-
ables in our experiment. Among these, we wanted to
exclude a potential effect of IL-33 present in the
injected serum, which might affect arthritis severity in
IL-33-deficient, but not in ST2 receptor-deficient mice.
The amount of IL-33 detected in different KBxN serum
pools (n = 4) used for arthritis induction was 77 ± 31
pg/ml (range < 4.3 to 139 pg/ml). Therefore, to avoid
co-injection of ‘contaminating’ IL-33 contained in the
serum as a potential confounding factor, we thus used
total IgG purified from K/BxN serum [29] to induce
arthritis. IL-33 levels were below the detection limit of
the Milliplex assay (4.3 pg/ml) in this purified IgG frac-
tion. Similarly to the experiment performed with com-
plete K/BxN serum, clinical scoring showed significantly
reduced incidence and severity of arthritis in ST2 KO
mice as compared to WT controls after injection of pur-
ified IgG (Figure 3A-C). In contrast, arthritis develop-
ment and severity in IL-33 KO mice was still similar to
that observed in WT controls. Therefore, a contribution
of IL-33 contained in the serum of K/BxN donor mice
to arthritis severity in IL-33 KO recipient mice can be
excluded.
Inhibition of ST2 signaling with a blocking antibody does
not reduce K/BxN serum transfer-induced arthritis
In an attempt to determine whether reduced arthritis
severity in ST2 KO mice might relate to a true IL-33 inde-
pendent effect of ST2 rather than to the existence of
confounding variables unrelated to ST2, we used a block-
ing anti-ST2 antibody [24,28] to inhibit ST2 signaling dur-
ing K/BxN serum transfer-induced arthritis (Figure 4).
Treatment of the mice with the anti-ST2 antibody before
and during development of arthritis did not reduce disease
severity in two independent experiments, while blocking
of the type 1 IL-1R with an isotype-matched anti-IL-1R1
blocking antibody essentially abrogated disease (Figure
4A-D). Histological severity scores confirmed clinical
severity data (data not shown).
Expression and function of other IL-1R family members in
IL-33 and ST2 KO mice
We next wondered whether the decreased severity of
arthritis observed in ST2 KO mice might be related to
off-target effects of the KO construct, rather than to dele-
tion of ST2 itself. The ST2 KO mice used in this study
were generated by replacement of exons 4 and 5 of the
ST2 gene with a neomycin selection cassette, which was
left in the locus [25]. There are many examples where
selection markers remain within targeted loci interfere
with the expression of neighboring genes or even entire
loci [35,36], so that nowadays more refined KO strategies,
allowing for the subsequent removal of selection markers,
are generally preferred. The mouse Il1rl1 gene encoding
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WT IL-33 KO ST2 KO
Figure 2 Synovial expression of IL-33 during KBxN serum transfer-induced arthritis. (A) Clinical scores for inflammation of the left hind
paw, which was processed for RNA extraction are shown (left panel), along with expression levels for IL-6 (middle panel) and IL-33 (right panel)
mRNAs in the joint. Transcript levels were normalized relative to Gapdh expression and represent the mean ± SEM for WT C57BL/6 (n = 14,
open columns), IL-33 KO (n = 12, gray columns), and ST2 KO (n = 10, black columns) mice. (B) Clinical scores for inflammation of the right
forepaw, which was processed for protein extraction are shown (left panel), along with IL-6 (middle panel) and IL-33 (right panel) protein
expression levels in the joint. Cytokine production was normalized to total protein content and represents the mean ± SEM for WT C57BL/6
(n = 14, open columns), IL-33 KO (n = 12, gray columns), and ST2 KO (n = 10, black columns) mice. (C) IL-33 protein expression (nuclear brown
staining) was assessed in the synovium of arthritic knee joints of WT (left panel), IL-33 KO (middle panel) and ST2 KO (right panel) mice
by immunohistochemistry (IHC) (original magnifications x200). Nuclear IL-33 staining was observed in WT and ST2 KO mice in cells
morphologically consistent with fibroblasts (arrows), as well as in other cell types, which were not formally identified (arrowheads). KO,
knockout; WT, wild-type.
Martin et al. Arthritis Research & Therapy 2013, 15:R13
http://arthritis-research.com/content/15/1/R13
Page 6 of 14
the ST2 receptor is located on chromosome 1, within a
cluster of genes encoding other receptors of the IL-1R
family, namely the type II decoy receptor for IL-1 (Il1r2),
the type I signaling IL-1R (Il1r1), the receptor for IL-36
(IL-36R, Il1rl2), as well as the receptor and co-receptor for
IL-18 (IL-18R, Il18r1 and IL-18R accessory protein,
Il18rap) (Figure 5A). Interference of ST2 targeting with
expression of any of these genes might in principle affect
arthritis severity. IL-1 activity, in particular, is known to be
absolutely required for joint inflammation in this model
[37]. We thus examined expression of the signaling IL-1,
IL-36 and IL-18 receptors (Figure 5B) and the responsive-
ness to cognate IL-1 family cytokines (Figure 5C) in vitro
in cultured BMDC derived from ST2 KO mice, as com-
pared to BMDC derived from WT and IL-33 KO mice.
BMDC were chosen as target cells because they respond
to all IL-1 family cytokines [31]. No significant differences
in IL-1, IL-36 and IL-18 receptor expression were
observed in BMDC derived from IL-33 KO or ST2 KO
mice, as compared to WT cells (Figure 5B). Furthermore,
the response of IL-33 KO and ST2 KO cells to IL-36 and
IL-18, as assessed by induction of IL-6 production, was
comparable to that of WT cells, while the response to IL-
1b was even slightly enhanced in ST2 KO cells. The
response to IL-33 was of course lost in ST2 KO cells and
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Figure 3 IL-33 deficiency does not reduce severity of arthritis induced by IgG purified from K/BxN serum. (A) Incidence of arthritis induced by
total IgG purified from K/BxN serum is shown for WT C57BL/6 mice (n = 10, dashed line), IL-33 KO mice (n = 9, gray line), and ST2 KO mice (n = 10,
black line). The incidence of arthritis was significantly retarded in ST2 KO, as compared to WT or IL-33 KO mice (P < 0.01, longitudinal model for
binomial data). Arthritis severity was evaluated by clinical assessment of arthritis severity scores (B) and number of affected paws (C) in WT C57BL/6
mice (n = 10, dashed line), IL-33 KO mice (n = 9, gray line), and ST2 KO mice (n = 10, black line). Results shown represent the mean ± SEM for each
group of mice. The evolution of severity scores (B; P < 0.01, mixed model for repeated measures) and of the number of affected paws (C, P < 0.001,
longitudinal model for ordinal data) was significantly decreased in ST2 KO, as compared to IL-33 KO and WT mice. In contrast, incidence and severity
of arthritis were similar in IL-33 KO and WT mice. IgG, immunoglobulin G; KO, knockout; WT, wild-type.
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(Figure 5C). LPS, used as an unrelated positive control, eli-
cited similar IL-6 production in IL-33 KO, ST2 KO and
WT BMDC. These data do not point toward any major
defect in expression of other IL-1R family receptors or in
IL-1 family cytokine signaling in ST2 KO cells.
Influence of genetic background on arthritis severity in
ST2 KO mice
IL-33 KO and ST2 KO mice were generated in 129Sv,
respectively 129P2/OlaHsd ES cells and backcrossed to
a C57BL/6 background. It has become increasingly clear
that despite extensive backcrossing, genetic material of
the original mouse strain, and in particular regions clo-
sely linked to the targeted loci, remains associated to
KOs in recipient strains, sometimes leading to con-
founding effects mistakenly attributed to the disrupted
gene [38,39]. We thus wondered whether carryover of
129 genetic material might have influenced the outcome
of our experiments. IL-33 KO mice were considered
100% C57BL/6 congenic at the end of their backcross
based on screening of a 377-marker panel. In addition,
at the end of the experiment shown in Figure 1, we
screened three mice per genotype using a 55-marker



































































0 1 2 3 4 5 6
A B
C D isotype control Ab
anti-ST2 Ab
anti-IL-1RI Ab
Figure 4 Inhibition of ST2, respectively IL-1R signaling with blocking antibody. (A, C) Incidence and (B, D) severity of K/BxN serum
transfer-induced arthritis are shown for WT C57BL/6 mice treated with blocking anti-ST2 antibody (n = 10, black line), blocking anti-IL-1R1
antibody (n = 10, gray dashed line) or isotype control antibody (n = 10, black dashed line) in two independent experiments (A, B: experiment 1;
C, D: experiment 2). Incidence of arthritis was markedly reduced (A, P < 0.01; C, P < 0.001, longitudinal model for binomial data) in anti-IL-1R1-
treated, as compared to anti-ST2 or isotype control antibody-treated mice. (B, D) Arthritis severity scores are shown as the mean ± SEM for each
group of mice. The evolution of arthritis severity scores (B, P < 0.001; D, P < 0.001, mixed model for repeated measures) and disease severity at
the end of the experiment were significantly reduced in anti-IL-1R1 antibody-treated, as compared to anti-ST2 or isotype control antibody-
treated mice (*P < 0.01 anti-IL-1R1 vs. isotype-control; &P < 0.01 anti-IL-1R1 vs. anti-ST2). Incidence and severity of arthritis were similar in anti-
ST2 and isotype control antibody-treated mice in both experiments. WT, wild-type.
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in our local mouse colonies. We confirmed 98% purity
of the C57BL/6 background in WT (one heterogeneous
marker: D4Mit166) and 100% purity in IL-33 KO mice.
Screening of ST2 KO mice revealed lower (89%) purity
(six heterogeneous markers: D1Mit211, D6Mi166,
D6Mit159, D6Mit102, D11Mit224, D15Mit193). We
further examined two additional markers close to the
Il1rl1 gene on chromosome 1 (D1Mit3 and D1Mit75a,
Figure 6A, Table 2), one of which (D1Mit3) was also
non-C57BL/6 in 17 out of 20 ST2 KO mice tested (Fig-
ure 6B and data not shown). In contrast, the D1Mit75a
and D1Mit303 markers, located downstream of the ST2
locus were C57BL/6 in all ST2 KO mice examined.









































































Figure 5 Expression and function of other IL-1R family members in IL-33 KO and ST2 KO BMDC. (A) Schematic representation of the IL-
1R gene cluster, including the ST2 gene Ilrl1, on mouse chromosome 1. Mb, megabase pairs. (B) Expression levels of mRNA for different IL-1R
family members encoded in this locus in WT, IL-33 KO and ST2 KO BMDC. Transcript levels were normalized to Gapdh expression and expressed
relative to values obtained in WT cells, which were arbitrarily set to 1. Data shown represent the mean ± SEM of three determinations in
independent cultures derived from IL-33 KO mice (grey columns), ST2 KO mice (black columns) or WT C57BL/6 mice (open columns). &P < 0.05
ST2KO vs. IL-33 KO cells, ANOVA. (C) Function of different IL-1R family members in cultured WT, IL-33 KO and ST2 KO BMDC. Induction of IL-6
production in response to 72 h of stimulation with different IL-1 family cytokines, namely IL-36, IL-1b, IL-18 and IL-33 (100 ng/ml) was monitored
in BMDC derived from IL-33 KO mice (grey columns), ST2 KO mice (black columns) or WT C57BL/6 mice (open columns). Lipopolysaccharide
(LPS) (100 ng/ml) stimulation was used as an unrelated positive control. Results are shown as mean ± SEM of values obtained in three
independent cultures. *P < 0.05 vs. WT cells; &P < 0.05 ST2KO vs. IL-33 KO cells, ANOVA. BMDC, bone marrow-derived dendritic cell; KO,
knockout; WT, wild-type.
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arthritis experiments (Figure 1 and 3) for the presence
of either C57BL/6, or 129 alleles at the D1Mit211,
D6Mi166, D6Mit159, D6Mit102, and D15Mit193 loci
and correlated their genotypes with arthritis severity of
individual mice (Figure 6C and data not shown). With
the limited number of mice included in these studies,
we observed no significant correlations. However, arthri-
tis severity in mice carrying two C57BL/6 alleles at a
given locus often tended to be lowest (D1Mit211,
D6Mit166; D6Mit159).
Discussion
Our results indicate that, although IL-33 is expressed in
the synovium during K/BxN serum transfer-induced
arthritis, IL-33 KO mice display similar arthritis severity
as compared to WT controls, suggesting that endogen-
ous IL-33 is not required for the development of joint
inflammation in this experimental model. Contrastingly,
disease severity was reduced in ST2 KO mice.
We thus confirm previous data indicating that ST2-defi-
cient mice have reduced severity of serum transfer-induced




















































Figure 6 Influence of 129 genetic background carryover on arthritis severity in ST2 KO mice. (A) Schematic representation of markers
screened on chromosome 1, cM 0-32. (B) Heterogeneity of genetic background in ST2 KO mice upstream of the ST2 locus on chromosome 1,
as assessed by size differences in markers D1Mit3 and D1Mit211, in the ST2 KO (n = 10, lanes 1 to 10) mice used for the arthritis experiment
shown in Figure 1. M, size ladder; B6, C57BL/6 control DNA; 129, 129SvPas control DNA; F1, B6x129F1 hybrid control DNA; bp, base pairs. (C)
Correlation of D1Mit211 (left panel), D6Mit159 (middle panel) and D15Mit193 (right panel) genotypes (B6, hybrid or 129) with maximal clinical
arthritis severity scores in the ST2 KO mice (n = 20) used for the arthritis experiments shown in Figure 1 and 3. Absolute values for arthritis
severity scores were corrected for overall mean maximal severity in each experiment. KO, knockout.
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arthritis [22]. However, this effect seems unrelated to the
role of endogenous IL-33 and we have not been able to
determine precisely why ST2 KO display less severe arthri-
tis. The reduction of joint inflammation in ST2 KO mice is
consistent in our hands and in experiments performed by
others [22] and this observation certainly merits further
investigation. Interestingly, we observed not only reduced
inflammation, but also reduced bone erosion in ST2 KO
mice. This finding is different from data reported pre-
viously [40,41], describing a deleterious effect of the ST2
KO on bone, at steady state and in the context of TNF-a-
induced arthritis. In contrast, in the present highly inflam-
matory model of arthritis, bone loss appeared to correlate
mostly with the degree of inflammation, rather than being
associated with a particular genotype.
In the course of these experiments, we observed nuclear
expression of the IL-33 protein in the arthritic synovium.
However, in striking contrast with human synovium [17]
and consistent with data in other mouse tissues [11], IL-33
expression was not detected in endothelial cells in arthritic
mouse paws. This observation emphasizes important dif-
ferences in IL-33 biology between human and mouse,
which need to be taken into account when inferring IL-33
function in human physiology or pathology from mouse
data.
Discrepant observations in studies using different ST2
KO lines, or even in different studies using the same
mouse line, as well as between ST2 KO and IL-33 KO
mice, have already been reported in other models, and in
particular in the context of allergic airway inflammation
[42-45]. However, this study is, to our knowledge, the
first instance where IL-33 and ST2 KO mice are com-
pared side by side in the same experiment. Our observa-
tion that endogenous IL-33 is not required for the
development of joint inflammation in serum transfer-
induced arthritis differs from previous conclusions based
on indirect evidence obtained using ST2 KO mice and
injections of recombinant IL-33 [22,23], suggesting that
caution is warranted when extrapolating such data to
conclude on functions of endogenous IL-33, as already
highlighted by other studies [46-48].
We considered a number of potential confounding
variables to explain our discrepant observations in IL-33
and ST2 KO mice. Among these, we excluded contami-
nation of injected serum with IL-33 to explain the lack
of difference between IL-33 KO and WT mice. We also
analyzed the potential interference of ST2 gene targeting
with expression of other IL-1R family receptors encoded
in the same gene cluster on mouse chromosome 1.
Using BMDC isolated from WT, IL-33 KO or ST2 KO
mice, we found no evidence for a major defect in
expression or function of one of these receptors in ST2
KO cells. However, based on our limited set of data, we
cannot exclude more subtle alterations in gene expres-
sion or signaling that might affect arthritis severity.
Furthermore, we serendipitously observed that, although
ST2 KO cells lack surface expression of ST2l ([25] and
our unpublished observations), and display no functional
response to IL-33 [49], the 3’ part of the ST2l mRNA is
still expressed in ST2 KO cells and tissues, to levels
similar to those detected in WT mice (PM et al., unpub-
lished observations). By 5’RACE, we localized the 5’ end
of the truncated ST2l transcript in ST2 KO cells to
exon 8 of the ST2 gene (bp 1081 of the ST2l cDNA,
GenBank accession NM_001025602). This transcript
includes an open reading frame potentially encoding a
truncated ST2l protein starting at amino acid 346,
which corresponds to the beginning of the intracellular
domain of the receptor. Although, due to lack of a suita-
ble antibody recognizing the intracellular part of mouse
ST2l, we have not been able to verify expression of a
truncated protein in ST2 KO mice, expression of a free
ST2 Toll/IL-1R (TIR) domain might conceivably inter-
fere with signaling of other IL-1R family receptors, by
analogy to regulation of IL-1R and Toll-like receptor
(TLR) signaling by the IL-1R family member SIGIRR
[50]. Interestingly, and whatever the mechanism invol-
ved, there is previous evidence for complex alterations
in the response to another IL-1 cytokine in ST2 KO
cells, with basophils of ST2 KO mice showing decreased
responses to IL-18 in terms of IL-4 and IL-13, but not
IL-6, production, as compared to WT cells [7].
We also considered the potential existence of micro-
RNAs (miRNAs) within and around the ST2 locus, the
expression of which might have been affected by ST2
targeting. To date, by searching miRBase [51], we found
no miRNA described in proximity of the Il1rl1 gene
(chromosome 1; 40.5 Mb), the closest miRNAs reported
being mmu-mir-5103 (miRBase accession number
MI0018011; 34.5 Mb) and mmu-mir-1928 (MI0009917;
74.3 Mb).
A previous study described higher severity of K/BxN
serum transfer-induced arthritis in C57BL/6, as com-
pared to 129 WT mice [52], and we wondered whether
carryover of genetic material from the original 129 strains
Table 2 Primer sequences for chromosome 1
microsatellite analysis.
Target Primer name Primer sequence
D1Mit3 D1Mit3 fwd 5’-tttttgttttcttttcttttccc-3’
D1Mit3 rev 5’-ccctcttctggtttccacat-3’
D1Mit211 D1Mit211 fwd 5’-gttattcatcaaaatacagatggcc-3’
D1Mit211 rev 5’-tctgctgctaagtagaatgaatgc-3’
D1Mit75a D1Mit75a fwd 5’-aaatcaccatggatttggttg-3’
D1Mit75a rev 5’-cctgtgccaacaaattaccc-3’
D1Mit303 D1Mit303 fwd 5’-ggtttctatttcggttctcgg-3’
D1Mit303 rev 5’-tctgtgctgcaaaacagagg-3’
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might have affected arthritis severity in the IL-33 and
ST2 lines used in this study. While IL-33 KO mice were
backcrossed to high purity to C57BL/6, the backcross
was less complete in ST2 KO mice, and we observed per-
sistence of non-C57BL/6 markers on chromosome 1,
close to the ST2 locus, but also on chromosomes 6, 11
and 15. However, in the regions examined, arthritis
severity often tended to be even less severe in the few
mice, which carried two C57BL/6 alleles, so that we can-
not provide evidence for any obvious effect of 129 carry-
over in decreasing joint inflammation. Nevertheless,
more complex genetic interactions among multiple chro-
mosomal sites acting to affect disease severity in these
mice cannot be excluded based on this limited analysis.
Obviously, an alternative explanation for the difference
in arthritis severity observed between ST2 and IL-33 KO
mice might lie with the existence of another ligand for
ST2, although we are not aware of data designating a can-
didate molecule for this function and we have been unable
to demonstrate any substantial binding interaction
between ST2 and any other IL-1 family member besides
IL-33. In an attempt to determine whether reduced arthri-
tis severity in ST2 KO mice might relate to a true IL-33
independent effect of ST2, we used blocking anti-ST2
antibodies to inhibit ST2 signaling during K/BxN serum
transfer-induced arthritis. In these experiments, treatment
of the mice with anti-ST2 antibodies did not reduce dis-
ease severity, while blocking of the type 1 IL-1R with an
isotype-matched anti-IL-1R1 blocking antibody essentially
abrogated disease. This observation suggests a minor con-
tribution, if any, of ST2 signaling to disease severity, as
opposed to a major contribution of IL-1R1, consistent
with the previously reported critical role of IL-1 in arthritis
pathogenesis in this model [37]. The anti-ST2 antibody
used efficiently prevented the biological activity of recom-
binant IL-33 in vitro and injected in vivo [24,28]. However,
it is unknown whether the IL-33 blocking ability of this
antibody would translate into the blocking of an IL-33-
independent activity. Furthermore, although suggested by
the efficacy of the anti-IL-1R1 antibody, complete target
coverage of the antibody within the joint over the whole
duration of the arthritis experiment seems difficult to ver-
ify. Therefore, although we consider it unlikely, we cannot
formally exclude a marginal role of ST2 signaling in the
pathogenesis of K/BxN serum transfer-induced arthritis.
In contrast to our present observations, we previously
reported that treatment with a blocking anti-ST2 anti-
body efficiently reduced disease severity in collagen-
induced arthritis, [18-21]. In fact, in mouse models of
arthritis involving active immunization, such as col-
lagen- or antigen-induced arthritis, the use of ST2 KO
mice, injection of anti-ST2 antibodies or treatment with
sST2 consistently led to decreased immune responses
and severity of arthritis [18-21]. Conversely, injection of
recombinant IL-33 enhanced disease severity, suggesting
a role for IL-33, signaling through ST2, in modulating
the pathogenic adaptive immune responses in these
models. Nevertheless, in the light of our present work, it
needs to be stressed that the contribution of endogen-
ous IL-33 has not been directly investigated in this con-
text and remains to be formally demonstrated.
Conclusions
These data indicate that, while IL-33 is expressed in the
synovium during K/BxN serum transfer-induced arthritis,
IL-33 KO mice displayed similar arthritis development
and severity as WT controls. Contrastingly, disease sever-
ity was reduced in ST2 KO mice; however, genetic analysis
revealed that the degree of backcrossing in ST2 KO mice
is much less complete. It is unclear, therefore, whether the
difference between IL-33 and ST2 KO mice relates to IL-
33 independent effects of ST2 or, instead, the existence of
confounding variables affecting the severity of joint inflam-
mation in these KO strains.
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